Clinical Progress and Treatment Result in Children with Acute Disseminated Encephalomyelitis.
- Author:
Yoon Seok CHOI
1
;
Jeong Cheol KANG
;
Young Mock LEE
;
Du Cheol KANG
;
Joon Soo LEE
;
Heung Dong KIM
;
Chang Jun COE
Author Information
1. Department of Pediatrics, Yonsei University, College of Medicine, Institute of Handicapped Children, Seoul, Korea. ped@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Acute disseminated encephalomyelitis
- MeSH:
Brain;
Central Nervous System;
Child*;
Demyelinating Diseases;
Dexamethasone;
Encephalomyelitis, Acute Disseminated*;
Humans;
Magnetic Resonance Imaging;
Methylprednisolone;
Prevalence;
Recurrence;
Retrospective Studies;
Steroids;
Vaccination
- From:
Journal of the Korean Child Neurology Society
2003;11(2):343-350
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Acute disseminated encephalomyelitis(ADEM) is a neurological disease that is commonly associated with previous history of infection or vaccination. It is mediated through immunological mechanisms, resulting in inflammatory demyelination of the central nervous system. The authors investigated the clinical, radiological features and disease progress of patients diagnosed with ADEM. METHODS: We have retrospectively reviewed 25 patients diagnosed with ADEM through neurological symptoms and brain MRI findings from July 1992 to July 2003. Patients were divided into three groups; patients treated with dexamethasone(group I), those with dexamethasone and immune globulin(group II), and those with methylprednisolone and immune globulin(group III). The neurological symptoms, time taken for recovery, recurrence rates and presence of neurologic residues were statistically analyzed. RESULTS: All 25 patients were treated with steroid, and 18 patients received immune globulin at the same time. Symptomatic improvements occurred 1 to 14 days with a mean of 6.9+/-4.0 days after administration of steroids. 6 patients displayed long-lasting sequelae, including 2 patients who relapsed. The average time taken for clinical improvements in various treatment groups were as follows; 7.5+/-2.1 days for group I(N=4), 7.3+/-5.1 days for group II(N=9), and 5.3+/-2.8 days for group III(N=4). Group III showed most rapid recovery without statistical significance. Differences in the rates of relapse and prevalence of neurological sequelae among those groups were statistically insignificant. CONCLUSION: The image detected on MRI and the clinical features of the patients did not differ from these of previously reported studies. The size of the sample was too small to acquire statistically significant results, but the patients who received methylprednisolone and immune globulin showed shortest recovery time, which might necessiate further studies.
